Gold Member Since 2012
YIHAN INDUSTRIAL CO., LIMITED

Flibanserin, Flibanserin Powder, Flibanserine Powder manufacturer / supplier in China, offering Women Sex Enhancement Agent Flibanserin Without Any Side Effect, Injectable Liquid Trenbolone Acetate 100mg/Ml Finaplix 100 Semi Oil, Professional Muscle Liquid Test Base & Testosterones Base & Testosterones (100mg/ml) and so on.

(/ )

Supplier Homepage Product Sex Enhancement Women Sex Enhancement Agent Flibanserin Without Any Side Effect

Women Sex Enhancement Agent Flibanserin Without Any Side Effect

Purchase Qty.:
(gram)
10-99 100+
FOB Unit Price: US $2 US $1
Purchase Qty. (gram) FOB Unit Price
10-99 US $2
100+ US $1
Get Latest Price
Port: Shenzhen, China
Production Capacity: 50 Tons/Month
Payment Terms: L/C, T/T, D/P, Western Union, Paypal, Money Gram

Request a custom order and have something just for you!

Send Customized Request
Basic Info
  • Model NO.: 167933-07-5
  • Customized: Non-Customized
  • Suitable for: Adult
  • Purity: >99%
  • CAS: 167933-07-5
  • MW: 294.17
  • Trademark: YIHAN
  • Specification: SGS. GMP
  • HS Code: 3001200020
  • Powder: Yes
  • Certification: GMP, ISO 9001, USP, BP
  • State: Solid
  • Mf: C20h21f3n4o
  • Name: Flibanserin
  • Package: Discreet Package
  • Transport Package: Discreet Package & Safe Shipping
  • Origin: China
Product Description

Quick Details:
 
Product NameFlibanserin
Chemical NameCentrophenoxine HCL
CAS Number167933-07-5
EINECS Number222-975-3
Molecular FormulaC20H21F3N4O
Molecular Weight294.17
Melting Point139-143ºC
Assay99.5%
AppearanceWhite powder

 
2.Product Description:

Flibanserin is a new drug being investigated for the prevention of HSDD in woman. HSDD, is a relatively new term developed to describe Hypoactive Sexual Desire Disorder which basically means a woman whose is otherwise healthy has a lacking libido, or a lack of sexual desire. Studies show that about 10-20% of women face this problem and some say HSDD outnumbers men with sexual problems. Flibanserin is classified as a 5-HT serotonin receptor agonist and a dopamine D4 receptor partial agonist. It is a Non-Hormonal agent that in essence increases dopamine and noradrenalin while reducing Serotonin in the brain. This in return seemingly has a positive effect on a woman's sexual craving who was otherwise lacking in this area. The benefits of it being Non-Hormonal are that it will not have the problems associated with other hormonal treatments such as a negative altered mood among other issues. 

Flibanserin is a novel, non-hormonal drug that has been studied in clinical trials for the treatment of HSDD in premenopausal and postmenopausal women. The application submitted to the FDA is for premenopausal women. Flibanserin is believed to work on key neurotransmitters, or chemicals, in the brain that affect sexual desire. More specifically, it is thought that flibanserin corrects an imbalance of levels of these neurotransmitters by increasing dopamine and norepinephrine (both responsible for sexual excitement) and decreasing serotonin (responsible for sexual inhibition). In clinical studies, flibanserin was evaluated for its ability to increase the frequency of satisfying sexual events, increase the intensity of sexual desire and decrease the associated distress women feel from its loss.

3.Product Application:

Flibanserin is used for hypoactive sexual desire disorder among women. Those receiving flibanserin report a 0.5 increase compared to placebo in the number of times they had "satisfying sexual events". In those on flibanserin it rose from 2.8 to 4.5 times a month while women receiving placebo reported also an increase of "satisfying sexual events" from 2.7 to 3.7 times a month. The onset of the flibanserin effect was seen from the first timepoint measured after 4 weeks of treatment and maintained throughout the treatment period.

The effectiveness of flibanserin was evaluated in three phase 3 clinical trials. Each of the three trials had two co-primary endpoints, one for satisfying sexual events (SSEs) and the other for sexual desire. Each of the 3 trials also had a secondary endpoint that measured distress related to sexual desire. All three trials showed that flibanserin produced a increase in the number of SSEs and reduced distress related to sexual desire. The first two trials used an electronic diary to measure sexual desire, and did not find an increase. These two trials also measured sexual desire using the Female Sexual Function index (FSFI) as a secondary endpoint, and a increase was observed using this latter measure. The FSFI was used as the co-primary endpoint for sexual desire in the third trial, and again showed a statistically significant increase.

4.COA:
 
TEST ITEMSSPECIFICATIONRESULTS
AppearanceWhite Or Practically White Crystalline PowderWhite Crystalline Powder
Melting range ≥145145-147
Loss on drying 0.5%max0.23%
Assay(by GLC)98.00%min99.30%

 5.Related Products:
 
Testosterone AcetateTrenbolone AcetateMGF
Testosterone CypionateTrenbolone EnanthatePEG MGF
Testosterone DecanoateBoldenone AcetateCJC-1295
Testosterone EnanthateBoldenone undecylenateCJC-1295 DAC
Testosterone IsocaproateBoldenone CypionatePT-141
TestosteronePhenylpropionateBoldenone PropionateMelanotan-1
Testosterone PropionateNandrolone DecanoateMelanotan-2
Testosterone UndecanoateNandrolone phenylpropionateGHRP-2
MesteroneNandrolone undecylateGHRP-6
Testosterone Sustanon 250Nandrolone cypionate Ipamorelin
Clostebol AcetateNandrolone propionateHexarelin
MethylandrostanoloneMethyltrienoloneSermorelin
Methenolone EnanthateDrostanolone PropionateOxytocin
Methenolone AcetateDrostanolone EnanthateTB500
AnadrolStanoloneFragment 176-191
AnavarTadalafilTriptorelin
WinstrolVardenafilTesamorelin
Clomifene citrateDianabolGonadorelin
Toremifene citrateTamoxifen CitrateDSIP 
FinasterideDapoxetine hydrochlorideSelank

 
Send your message to this supplier
Avatar
Ms. Anna Liu
Sales Manager
*From:
To: Ms. Anna Liu
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now

Find Similar Products By Category